276 related articles for article (PubMed ID: 17690987)
1. An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy.
Attanasio R; Montini M; Valota M; Cortesi L; Barbò R; Biroli F; Tonnarelli G; Albizzi M; Testa RM; Pagani G
Pituitary; 2008; 11(1):1-11. PubMed ID: 17690987
[TBL] [Abstract][Full Text] [Related]
2. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
3. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
4. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
5. Therapy for the syndromes of GH excess.
Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry].
Jaquet P; Cortet-Rudelli Ch; Sassolas G; Morange-Ramos I; Chanson P; Brue T; Andrieu JM; Beckers A; Bertherat J; Borson-Chazot F; Brassier G; Caron P; Cogne M; Cottier JP; Delemer B; Dufour H; Enjalbert A; Figarella-Branger D; Gaillard R; Gueydan M; Jan M; Kuhn JM; Raingeard I; Regis J; Roger P; Rohmer V; Sadoul JL; Saveanu A; Tabarin A; Travers N; Trouillas J;
Ann Endocrinol (Paris); 2003 Dec; 64(6):434-41. PubMed ID: 15067248
[TBL] [Abstract][Full Text] [Related]
8. Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients.
Albarel F; Castinetti F; Morange I; Conte-Devolx B; Gaudart J; Dufour H; Brue T
Clin Endocrinol (Oxf); 2013 Feb; 78(2):263-70. PubMed ID: 22783815
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?
Gatto F; Grasso LF; Nazzari E; Cuny T; Anania P; Di Somma C; Colao A; Zona G; Weryha G; Pivonello R; Ferone D
Pituitary; 2015 Oct; 18(5):583-91. PubMed ID: 25326851
[TBL] [Abstract][Full Text] [Related]
10. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
Maiza JC; Vezzosi D; Matta M; Donadille F; Loubes-Lacroix F; Cournot M; Bennet A; Caron P
Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
12. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
Kreutzer J; Vance ML; Lopes MB; Laws ER
J Clin Endocrinol Metab; 2001 Sep; 86(9):4072-7. PubMed ID: 11549628
[TBL] [Abstract][Full Text] [Related]
13. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
14. Failure of radiotherapy in acromegaly.
Cozzi R; Barausse M; Asnaghi D; Dallabonzana D; Lodrini S; Attanasio R
Eur J Endocrinol; 2001 Dec; 145(6):717-26. PubMed ID: 11720896
[TBL] [Abstract][Full Text] [Related]
15. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly.
Jenkins D; O'Brien I; Johnson A; Shakespear R; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1995 Nov; 43(5):517-22. PubMed ID: 8548933
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
17. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
18. CyberKnife robotic radiosurgery in the multimodal management of acromegaly patients with invasive macroadenoma: a single center's experience.
Sala E; Moore JM; Amorin A; Martinez H; Bhowmik AC; Lamsam L; Chang S; Soltys SG; Katznelson L; Harsh GR
J Neurooncol; 2018 Jun; 138(2):291-298. PubMed ID: 29429125
[TBL] [Abstract][Full Text] [Related]
19. Current management of acromegaly.
Díez JJ; Iglesias P
Expert Opin Pharmacother; 2000 Jul; 1(5):991-1006. PubMed ID: 11249504
[TBL] [Abstract][Full Text] [Related]
20. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
